U.S. FDA Panel Mulls Safety Of Luitpold’s Intravenous Iron
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's Drug Safety and Risk Advisory Committee meets Feb. 1 to discuss patient deaths in trials of Daiichi Sankyo's U.S. subsidiary Luitpold's Injectafer (ferric carboxymaltose) for treatment of anemia in postpartum patients and those with heavy uterine bleeding